Vitality Watch

Dossier pubmed trial late 29-jun-2026
Large or late-phase randomized human trial

Personalized blood flow restriction training at variable occlusion pressures improves multisystem function in overweight and obese older women.

Key claim: Twelve weeks of low-intensity blood flow restriction training at 60–70% arterial occlusion pressure produced dose-dependent improvements in inflammatory, muscular, metabolic, and cardiopulmonary function in overweight and obese older women, with high adherence and few minor adverse events.

Abstract

This study investigated the effects of 12-week low-intensity blood flow restriction (BFR) training at different arterial occlusion pressure (AOP) levels on cardiopulmonary, immune, muscular, and metabolic functions in overweight and obese older women. A total of 180 community-dwelling women aged ≥ 60 years with body mass index ≥ 25.0 kg/m² were randomly allocated to BFR training groups at 50%, 60%, or 70% AOP or a control group performing identical exercises without pressure. Participants completed supervised training sessions three times weekly for 12 weeks. BFR training induced significant improvements across all physiological systems, with dose-dependent responses correlating with AOP levels. The 70% AOP group demonstrated the greatest reductions in inflammatory markers (IL-6: -28.4%; hs-CRP: -35.7%), the largest gains in muscle hypertrophy (quadriceps thickness: +10.2%), and the most pronounced improvements in metabolic parameters (HOMA-IR: -25.0%). Obese women showed greater absolute improvements in inflammatory and metabolic markers compared to overweight participants. Most improvements were maintained at 24-week follow-up, particularly anti-inflammatory effects in the higher pressure group. The findings establish 60-70% AOP as the optimal range for maximizing multi-system adaptations while maintaining safety. BFR training represents a safe and effective low-load exercise modality for older women, offering comprehensive physiological benefits with high adherence rates (90.7-93.1%) and a low rate of minor adverse events (12.2%), none requiring medical intervention, with 60% AOP recommended as the optimal starting pressure and 70% AOP for individuals requiring maximal cardiometabolic benefits. These findings have potential implications for populations with treatment-related deconditioning, including cancer survivors, though further investigation is warranted.

Why this matters

BFR research in older adults has mostly tested single-system endpoints (hypertrophy, capillarization, or pulmonary volumes) in small or already-trained cohorts; this is a larger dose-finding RCT in overweight/obese older women that reads out inflammatory, muscular, metabolic, and cardiopulmonary endpoints together and finds dose-dependent effects between 60% and 70% arterial occlusion pressure. That matters for the vault’s exercise-prescription map because it begins to resolve the occlusion-dose question in a demographic that typically tolerates neither high-load resistance training nor high-intensity aerobic work, while still leaving pressure-selection and durability beyond 12 weeks open.

Source

Link

Briefing card

Personalized blood flow restriction training at variable occlusion pressures improves multisystem function in overweight and obese older women.
Stage: trial late · pubmed · 29-jun-2026

If you are an overweight or obese older woman considering blood flow restriction training, this trial found 60–70% arterial occlusion pressure produced dose-dependent gains across inflammation, strength, metabolism, and cardiopulmonary function over 12 weeks with few minor adverse events.

Twelve weeks of low-intensity blood flow restriction training at 60–70% arterial occlusion pressure produced dose-dependent improvements in inflammatory, muscular, metabolic, and cardiopulmonary function in overweight and obese older women, with high adherence and few minor adverse events.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1007/s00421-026-06299-2

build build 880 · 2bcef25 · 2026-11-18